<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361708</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-1292</org_study_id>
    <nct_id>NCT04361708</nct_id>
  </id_info>
  <brief_title>Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies</brief_title>
  <acronym>I-FLOAT</acronym>
  <official_title>A Phase 1 Dose Finding Study of the gFOLFOXIRITAX Regimen Using UGT1A1 Genotype-directed Irinotecan With Fluorouracil, Leucovorin, Oxaliplatin and Taxotere in Patients With Untreated Advanced Upper Gastrointestinal Adenocarcinomas: The I-FLOAT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to establish the safety of combining irinotecan&#xD;
      chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as&#xD;
      the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to&#xD;
      make 5-FU work well).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum dose tolerated</measure>
    <time_frame>1 month</time_frame>
    <description>To determine the maximum tolerated dose in the first month of therapy in each of the three main genotype groups (low, intermediate, and high risk) using genotype-guided dosing of irinotecan as part of the I-FLOAT regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of each chemotherapy drug</measure>
    <time_frame>4 months</time_frame>
    <description>To determine the cumulative dose of each chemotherapy drug (irinotecan, 5-FU, oxaliplatin, docetaxel) administered in each genotype group over a period of 4 months (8 doses).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of therapy</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the total duration of therapy, which would be administered perioperatively in future studies for the curative-intent setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>5 years</time_frame>
    <description>To determine early efficacy (overall responsive rate, progression free survival, and overall survival) in all patients enrolled and treated in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>To determine early efficacy (overall responsive rate, progression free survival, and overall survival) in all patients enrolled and treated in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>To determine early efficacy (overall responsive rate, progression free survival, and overall survival) in all patients enrolled and treated in the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>High Risk UGT1A1 genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Risk UGT1A1 genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Risk UGT1A1 genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)</description>
    <arm_group_label>High Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Intermediate Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Low Risk UGT1A1 genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)</description>
    <arm_group_label>High Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Intermediate Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Low Risk UGT1A1 genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)</description>
    <arm_group_label>High Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Intermediate Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Low Risk UGT1A1 genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)</description>
    <arm_group_label>High Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Intermediate Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Low Risk UGT1A1 genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.</description>
    <arm_group_label>High Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Intermediate Risk UGT1A1 genotype</arm_group_label>
    <arm_group_label>Low Risk UGT1A1 genotype</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed locally advanced or metastatic pancreatic&#xD;
             adenocarcinoma, gastroesophageal adenocarcinoma, cholangiocarcinoma, gallbladder&#xD;
             adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with upper GI&#xD;
             primary suspected), or other primary GI malignancy for which the treating physician&#xD;
             feels that I-FLOAT is a reasonable therapeutic option.&#xD;
&#xD;
          2. Patients with a history of obstructive jaundice due to the primary tumor must have&#xD;
             resolved to &lt;1.5 X upper limit of normal and a metal biliary stent in place&#xD;
&#xD;
          3. Age greater than or equal to 18 years.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status =1&#xD;
&#xD;
          5. Life expectancy &gt; 3 months&#xD;
&#xD;
          6. Adequate organ function, as defined by each of the following:&#xD;
&#xD;
             Absolute neutrophil count (ANC) = 1500/uL Hemoglobin &gt; 9g/dL (transfusion permitted&#xD;
             with stability for &gt; 1 week) Platelets &gt; 100,000/uL Total bilirubin = 1.5 mg/dL AST&#xD;
             and ALT = 2.5 X upper limit of normal; alkaline phosphatase = 2.5 X upper limit of&#xD;
             normal, unless bone metastasis is present in the absence of liver metastasis.&#xD;
&#xD;
             AST and ALT = 5 X upper limit of normal if hepatic metastases are present. Creatinine&#xD;
             = 1.5 mg/dL&#xD;
&#xD;
          7. Measurable or non-measurable disease will be allowed.&#xD;
&#xD;
          8. Women of childbearing potential and sexually active males must use an effective&#xD;
             contraception method during treatment and for three months after completing treatment.&#xD;
&#xD;
          9. Negative serum or urine B-hCG pregnancy test at screening for patients of childbearing&#xD;
             potential&#xD;
&#xD;
         10. Patients taking substrates, inhibitors, or inducers of CYP3A4 should be encouraged to&#xD;
             switch to alternative drugs whenever possible, given the potential for drug-drug&#xD;
             interactions with irinotecan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior radiation therapy for any cancer.&#xD;
&#xD;
          2. Prior chemotherapy for metastatic disease Recurrence of disease within 6 months of&#xD;
             perioperative chemotherapy are eligible if other eligibility criteria are met&#xD;
&#xD;
          3. Inflammatory bowel disease (Crohn's disease, ulcerative colitis)&#xD;
&#xD;
          4. Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology&#xD;
             Criteria for Adverse Events (NCI-CTCAE, v. 4.0*). Pancreatic cancer patients with&#xD;
             clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme&#xD;
             replacement.&#xD;
&#xD;
          5. Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0.&#xD;
&#xD;
          6. Documented brain metastases&#xD;
&#xD;
          7. Serious underlying medical or psychiatric illnesses that would, in the opinion of the&#xD;
             treating physician, substantially increase the risk for complications related to&#xD;
             treatment.&#xD;
&#xD;
          8. Active uncontrolled bleeding.&#xD;
&#xD;
          9. Pregnancy or breastfeeding.&#xD;
&#xD;
         10. Major surgery within 4 weeks.&#xD;
&#xD;
         11. Previous or concurrent malignancy, except for adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the&#xD;
             patient has been previously treated and the lifetime recurrence risk is less than 30%,&#xD;
             and meets all other eligibility criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Catenacci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Catenacci, MD</last_name>
    <phone>773-702-7596</phone>
    <email>dcatenacci@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Intake</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Catenacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

